Our team at the University of Minnesota, along with partners at Northwester University, UCLA – Olive View, University of Colorado – Denver, and Hennepin Counter Medical Center have launched a factorial design, randomized clinical trial hoping to identify what, if any, effect metformin, ivermectin, and fluvoxamine may have on early, mild to moderate COVID.
Briefly, we are looking for people who are 30 – 85 years old with a positive COVID test in the past 3 days who are intersted in helping us determine if one or more of these cheap, widely available, and widely used medications (or a combintion of two of them) might have activity against early COVID and reduce the severity of symptoms and risk of progressing to more severe forms of the disease. Those who qualify and enroll would be randomized to received one of six regimens (metformin, metformin + ivermectin, fluvoxamine, fluvoxamine + metformin, or placebo, meaning you only have a 17% chance of receiving placebo). You would take the medication for 14 days, and then complete online follow-up surveys asking about your symptoms. The study does not require clinic visits or bloodwork, and is conducted entirely online/through the mail.
If you’re interested or want more information, check out our website at https://covidout.umn.edu